Solbec granted patent
Thursday, 29 September, 2005
Solbec Pharmaceuticals (ASX:SBP) has been granted an Australian patent giving the company the monopoly right to prevent others from isolating the rhamnose binding protein receptor of its lead compound Coramsine.
Last month Solbec was granted a US patent based on the same inventive material. The RBP receptor is over-expressed in mammalian cancer cells, but not in healthy cells, and explains why Solbec's Coramsine is selective in targeting cancer cells.
The term of the patent runs until February 2023.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
